InvestorsHub Logo
Followers 116
Posts 33453
Boards Moderated 3
Alias Born 10/22/2007

Re: None

Friday, 06/04/2010 6:53:10 AM

Friday, June 04, 2010 6:53:10 AM

Post# of 71
FDAnews Drug Daily Bulletin
June 4, 2010 | Vol. 7 No. 109

Antisoma’s AS1413 Gains FDA Fast Track Status for Myeloid Leukemia
Cancer drug developer Antisoma Thursday announced that the FDA has granted Fast Track designation to the Company’s novel DNA intercalator, AS1413 (amonafide L-malate), for the treatment of secondary acute myeloid leukemia.



http://www.fdanews.com/newsletter/article?issueId=13751&articleId=127580


Longterm Investment, Biotechs & High Yield Dividend Stocks ... #board-11828

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ASM News